Who were the partners in this research project?

The joint research involved ExaWizards, ExaMD, Kansai Medical University, and Daiichi Sankyo, among others.

Where were the findings presented?

The findings were presented at ASCO 2026 (the American Society of Clinical Oncology conference).

AI in HealthcareTop Companies' AI MovesTop Companies AIJul 16, 2026Jul 17, 2026, 06:31 JST1 min read

ExaWizards、乳がん患者向けウェアラブル研究をASCO 2026で発表

Send on LINE

Key takeaway

ExaWizards and ExaMD presented results from a wearable device study on breast cancer patients at ASCO 2026, a major international oncology conference.
The research was conducted jointly with Kansai Medical University and Daiichi Sankyo, representing collaboration between Japanese AI/healthcare companies and leading pharmaceutical and academic partners to advance patient monitoring technology.

3 Key Points

What happened
ExaWizards and ExaMD presented findings from a wearable device study on breast cancer patients at the American Society of Clinical Oncology's ASCO 2026 conference. The research was a joint project involving Kansai Medical University, Daiichi Sankyo, and others.
Why it matters
The study represents collaboration between a Japanese AI/healthcare company and major pharmaceutical and academic institutions to develop wearable technology for cancer patient monitoring. Presenting at ASCO, a leading global oncology forum, signals the research meets international clinical standards.
What to watch
The specific findings and clinical implications of the wearable device study will be detailed in the ASCO 2026 presentation, though the full results are not yet disclosed in this announcement.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Get news like this every morning — free

Context & Analysis

ExaWizards and ExaMD's presentation at ASCO 2026 marks a notable step in bringing Japanese technology companies into the international clinical research sphere. The partnership with Kansai Medical University and Daiichi Sankyo—a major Japanese pharmaceutical corporation—demonstrates a coordinated approach to wearable monitoring for oncology patients. By presenting at ASCO, one of the world's premier gatherings for cancer researchers and clinicians, the team is seeking validation and visibility for its work within the global medical community. The specific focus on breast cancer patients suggests a targeted application where wearable devices could support continuous monitoring, potentially improving treatment outcomes or patient management.

FAQ

Who were the partners in this research project?: The joint research involved ExaWizards, ExaMD, Kansai Medical University, and Daiichi Sankyo, among others.
Where were the findings presented?: The findings were presented at ASCO 2026 (the American Society of Clinical Oncology conference).